Managed Healthcare Executive January 15, 2021
The industry is adjusting to the pandemic, but FDA approvals could dip this year. Several new drugs for atopic dermatitis may get the agency’s green light.
Like so much else in healthcare and beyond, a large question hangs over drug development in 2021 and the pace of FDA approvals: How much of an effect will COVID-19 have?
Because the majority of FDA approvals in the latter part of 2020 were based on results of trials conducted before the pandemic, the full impact of the pandemic on approvals may not become evident till this year. When the pandemic reached the United States in March and lockdowns throughout the country began, some active trials paused, many trials set to start were delayed,...
Today's Sponsors
Today's Sponsor